Meanwhile, in 2019, the US FDA also approved another A2AR antagonist, istradefylline, as an add-on treatment to levodopa for Parkinson’s disease (PD) “OFF” episodes (Chen and Cunha, 2020). The gene discussed is ADORA2A; the disease is Parkinson disease.